Ligand Pharm (LGND)

$274.88 +11.74 (4.46%)
Market Cap 5.27B
Revenue (ttm) 268.09M
Net Income (ttm) 124.45M
EPS (ttm) N/A
PE Ratio 34.63
Forward PE 57.07
Profit Margin 46.42%
Debt to Equity Ratio 0.00
Volume 609,500
Avg Vol 219,640
Day's Range N/A - N/A
Shares Out 20.04M
Stochastic %K 87%
Beta 1.17
Analysts Strong Sell
Price Target $271.00

Company Profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also pr...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 550 7500
Address:
555 Heritage Drive, Suite 200, Jupiter, United States
JamesTaulman
JamesTaulman Jun. 19 at 2:47 AM
$LGND – THU: Continued Bullish Action With Volume-Backed Gains to New Highs 8:30 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/thu-6-18-lgnd-continued-bullish-action-with-volume-backed-gains-to-new-highs/
0 · Reply
Jwa68
Jwa68 Jun. 18 at 12:42 PM
$PTHS A $1M insider purchase from the CEO of $LGND.. let that sit in...
0 · Reply
Doozio
Doozio Jun. 17 at 9:24 PM
$XBI has been up 12 of the last 13 months and 13 of the last 15 since 🐒🍌🧠⏰♾️ began. They did say it wud get $LGND ary with a $LEGN of huckleberries.
1 · Reply
Jwa68
Jwa68 Jun. 16 at 12:41 PM
$PTHS Not just anyone buying $1M worth, but the CEO of $LGND ....pretty telling.
0 · Reply
JamesTaulman
JamesTaulman Jun. 16 at 2:18 AM
$LGND – MON: Welcomed Quieter Trading After Several Sessions With Above Average Volume Gains 7:45 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/mon-6-15-lgnd-welcomed-quieter-trading-after-several-sessions-with-above-average-volume-gains/
0 · Reply
JamesTaulman
JamesTaulman Jun. 12 at 3:46 AM
$LGND – THU: Solid Gains With a +22% Increase in Volume – New High Close 11:00 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/thu-6-11-lgnd-solid-gains-with-a-22-increase-in-volume-new-high-close/
0 · Reply
JamesTaulman
JamesTaulman Jun. 11 at 2:45 AM
$LGND – WED: Jumped Higher Then Pulled Back – Next Support Is at the Round-$240 8:00 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/wed-6-10-lgnd-jumped-higher-then-pulled-back-next-support-is-at-the-round-240/
0 · Reply
xUltraCash
xUltraCash Jun. 10 at 2:22 PM
$LGND nice..
0 · Reply
JamesTaulman
JamesTaulman Jun. 10 at 2:53 AM
$LGND – TUE: Posts a New High Close Yet Volume Off -20% 8:45 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/tue-6-9-lgnd-posts-a-new-high-close-yet-volume-off-20/
0 · Reply
JamesTaulman
JamesTaulman Jun. 9 at 2:43 AM
$LGND – MON: Dealing With Some Noted Resistance of the Round-$240 9:30 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/mon-6-8-lgnd-dealing-with-some-noted-resistance-of-the-round-240/
0 · Reply
Latest News on LGND
Ligand Announces 2026 Investor Day in New York City

Jun 10, 2026, 7:00 AM EDT - 9 days ago

Ligand Announces 2026 Investor Day in New York City

Ligand price target raised to $266 from $263 at BofA

2026-05-28T14:28:37.000Z - 22 days ago

Ligand price target raised to $266 from $263 at BofA

TVTX

Ligand to Participate in June Investor Conferences

May 27, 2026, 4:01 PM EDT - 22 days ago

Ligand to Participate in June Investor Conferences

Ligand Pharmaceuticals Proxy statement: Proxy filing

May 18, 2026, 8:00 AM EDT - 4 weeks ago

Ligand Pharmaceuticals Proxy statement: Proxy filing

Ligand reports Q1 adjusted EPS $1.63, consensus $1.80

2026-05-07T15:17:53.000Z - 6 weeks ago

Ligand reports Q1 adjusted EPS $1.63, consensus $1.80

Ligand backs FY26 adjusted EPS view $8.50-$9.50, consensus $9.21

2026-05-07T15:12:18.000Z - 6 weeks ago

Ligand backs FY26 adjusted EPS view $8.50-$9.50, consensus $9.21

Ligand Pharmaceuticals Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 6 weeks ago

Ligand Pharmaceuticals Earnings Call Transcript: Q1 2026

Ligand Pharmaceuticals Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 6 weeks ago

Ligand Pharmaceuticals Earnings release: Q1 2026

Ligand Pharmaceuticals Slides: Q1 2026

May 7, 2026, 8:30 AM EDT - 6 weeks ago

Ligand Pharmaceuticals Slides: Q1 2026

Ligand Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 8:30 AM EDT - 6 weeks ago

Ligand Pharmaceuticals Quarterly report: Q1 2026

Ligand Reports First Quarter 2026 Financial Results

May 7, 2026, 7:00 AM EDT - 6 weeks ago

Ligand Reports First Quarter 2026 Financial Results

Orchestra BioMed receives $15M payment from Ligand

2026-05-07T05:00:15.000Z - 6 weeks ago

Orchestra BioMed receives $15M payment from Ligand

OBIO

Ligand to Participate in May Investor Conferences

May 5, 2026, 4:01 PM EDT - 6 weeks ago

Ligand to Participate in May Investor Conferences

Ligand price target raised to $289 from $243 at H.C. Wainwright

2026-04-30T10:10:18.000Z - 7 weeks ago

Ligand price target raised to $289 from $243 at H.C. Wainwright

Ligand price target raised to $252 from $235 at RBC Capital

2026-04-28T12:05:59.000Z - 7 weeks ago

Ligand price target raised to $252 from $235 at RBC Capital

Ligand Pharmaceuticals Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 7 weeks ago

Ligand Pharmaceuticals Proxy statement: Proxy filing

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation

Apr 27, 2026, 3:06 PM EDT - 7 weeks ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation

XOMA

Ligand price target raised to $255 from $230 at Stifel

2026-04-27T18:10:15.000Z - 7 weeks ago

Ligand price target raised to $255 from $230 at Stifel

XOMA

Ligand price target raised to $260 from $250 at BofA

2026-04-27T18:00:17.000Z - 7 weeks ago

Ligand price target raised to $260 from $250 at BofA

XOMA

Ligand Pharma to buy fellow biotech royalty rights buyer XOMA for $739 million

Apr 27, 2026, 8:12 AM EDT - 7 weeks ago

Ligand Pharma to buy fellow biotech royalty rights buyer XOMA for $739 million

Ligand Pharmaceuticals Transcript: M&A announcement

Apr 27, 2026, 8:00 AM EDT - 7 weeks ago

Ligand Pharmaceuticals Transcript: M&A announcement

Ligand Pharmaceuticals Press release: M&A announcement

Apr 27, 2026, 8:00 AM EDT - 7 weeks ago

Ligand Pharmaceuticals Press release: M&A announcement

Ligand Pharmaceuticals Slides: M&A announcement

Apr 27, 2026, 8:00 AM EDT - 7 weeks ago

Ligand Pharmaceuticals Slides: M&A announcement

Ligand Pharmaceuticals Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 7 weeks ago

Ligand Pharmaceuticals Proxy statement: Proxy filing

Ligand to acquire Xoma for $39.00 per share in cash

2026-04-27T11:26:31.000Z - 7 weeks ago

Ligand to acquire Xoma for $39.00 per share in cash

XOMA

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator

Apr 27, 2026, 7:00 AM EDT - 7 weeks ago

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator

XOMA

Ligand to buy Xoma for $39 per share, WSJ reports

2026-04-27T10:38:33.000Z - 7 weeks ago

Ligand to buy Xoma for $39 per share, WSJ reports

XOMA

Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million

Apr 27, 2026, 6:00 AM EDT - 7 weeks ago

Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million

Coave Therapeutics to present two posters at ARVO 2026, on first-in-class ligand-conjugated suprachoroidal vector and lead gene therapy program

Apr 22, 2026, 7:00 AM EDT - 2 months ago

Coave Therapeutics to present two posters at ARVO 2026, on first-in-class ligand-conjugated suprachoroidal vector and lead gene therapy program

Ligand to Report First Quarter 2026 Financial Results on May 7, 2026

Apr 22, 2026, 7:00 AM EDT - 2 months ago

Ligand to Report First Quarter 2026 Financial Results on May 7, 2026

Ligand Pharmaceuticals Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 2 months ago

Ligand Pharmaceuticals Proxy statement: Proxy filing

Ligand Pharmaceuticals Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 2 months ago

Ligand Pharmaceuticals Proxy statement: Proxy filing

Ligand price target raised to $282 from $276 at Citi

2026-04-15T10:46:47.000Z - 2 months ago

Ligand price target raised to $282 from $276 at Citi

Ligand price target raised to $250 from $244 at BofA

2026-04-14T11:19:24.000Z - 2 months ago

Ligand price target raised to $250 from $244 at BofA

TVTX

Ligand partner Travere Therapeutics announces FDA approval for Filspari

2026-04-14T11:10:41.000Z - 2 months ago

Ligand partner Travere Therapeutics announces FDA approval for Filspari

TVTX

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS

Apr 14, 2026, 7:00 AM EDT - 2 months ago

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS

Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team

Mar 26, 2026, 7:00 AM EDT - 3 months ago

Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team

Citi ups Ligand target, opens ‘upside 90-day catalyst watch’

2026-03-24T10:05:12.000Z - 3 months ago

Citi ups Ligand target, opens ‘upside 90-day catalyst watch’

Ligand initiated with a Buy at BofA

2026-03-11T10:11:59.000Z - 3 months ago

Ligand initiated with a Buy at BofA

Ligand to Participate in March Investor Conferences

Mar 4, 2026, 7:00 AM EST - 3 months ago

Ligand to Participate in March Investor Conferences

Ligand files automatic mixed securities shelf

2026-02-27T22:30:35.000Z - 3 months ago

Ligand files automatic mixed securities shelf

Ligand Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 4 months ago

Ligand Pharmaceuticals Earnings Call Transcript: Q4 2025

Ligand Pharmaceuticals Annual report: Q4 2025

Feb 26, 2026, 8:30 AM EST - 4 months ago

Ligand Pharmaceuticals Annual report: Q4 2025

Ligand Pharmaceuticals Earnings release: Q4 2025

Feb 26, 2026, 8:30 AM EST - 4 months ago

Ligand Pharmaceuticals Earnings release: Q4 2025

Ligand Pharmaceuticals Slides: Q4 2025

Feb 26, 2026, 8:30 AM EST - 4 months ago

Ligand Pharmaceuticals Slides: Q4 2025

Ligand Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 26, 2026, 7:00 AM EST - 4 months ago

Ligand Reports Fourth Quarter and Full Year 2025 Financial Results

Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Feb 12, 2026, 7:00 AM EST - 4 months ago

Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 4, 2026, 7:00 AM EST - 4 months ago

Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Ligand Pharmaceuticals Transcript: Investor Day 2025

Dec 9, 2025, 10:30 AM EST - 6 months ago

Ligand Pharmaceuticals Transcript: Investor Day 2025

Ligand Pharmaceuticals Press release: FY 2025

Dec 9, 2025, 10:30 AM EST - 6 months ago

Ligand Pharmaceuticals Press release: FY 2025

Ligand Pharmaceuticals Slides: FY 2025

Dec 9, 2025, 10:30 AM EST - 6 months ago

Ligand Pharmaceuticals Slides: FY 2025

Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

Dec 9, 2025, 7:00 AM EST - 6 months ago

Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

Ligand Pharmaceuticals Transcript: 17th Annual Southwest IDEAS Conference

Nov 20, 2025, 2:20 PM EST - 7 months ago

Ligand Pharmaceuticals Transcript: 17th Annual Southwest IDEAS Conference

Ligand Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Ligand Pharmaceuticals Earnings Call Transcript: Q3 2025

Ligand Pharmaceuticals Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Ligand Pharmaceuticals Quarterly report: Q3 2025

Ligand Pharmaceuticals Earnings release: Q3 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Ligand Pharmaceuticals Earnings release: Q3 2025

Ligand Pharmaceuticals Slides: Q3 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Ligand Pharmaceuticals Slides: Q3 2025

Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance

Nov 6, 2025, 7:00 AM EST - 8 months ago

Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance

Ligand to Participate in November Investor Conferences

Oct 30, 2025, 4:01 PM EDT - 8 months ago

Ligand to Participate in November Investor Conferences

Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 23, 2025, 7:00 AM EDT - 8 months ago

Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025

Ligand to Host Investor Day on December 9, 2025

Oct 16, 2025, 7:00 AM EDT - 8 months ago

Ligand to Host Investor Day on December 9, 2025

Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients

Oct 9, 2025, 7:00 AM EDT - 9 months ago

Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients

Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292

Sep 25, 2025, 2:30 AM EDT - 9 months ago

Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292

Ligand Pharmaceuticals Transcript: 16th Annual Midwest Ideas Conference

Aug 27, 2025, 3:00 PM EDT - 10 months ago

Ligand Pharmaceuticals Transcript: 16th Annual Midwest Ideas Conference

Ligand to Participate in September Investor Conferences

Aug 19, 2025, 4:00 PM EDT - 10 months ago

Ligand to Participate in September Investor Conferences

Ligand Announces Closing of Convertible Senior Notes Offering

Aug 14, 2025, 4:00 PM EDT - 11 months ago

Ligand Announces Closing of Convertible Senior Notes Offering

Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering

Aug 11, 2025, 11:46 PM EDT - 11 months ago

Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering

Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030

Ligand Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 11 months ago

Ligand Pharmaceuticals Earnings Call Transcript: Q2 2025

Ligand Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 11 months ago

Ligand Pharmaceuticals Quarterly report: Q2 2025

Ligand Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 11 months ago

Ligand Pharmaceuticals Earnings release: Q2 2025

Ligand Pharmaceuticals Slides: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 11 months ago

Ligand Pharmaceuticals Slides: Q2 2025

Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance

Aug 7, 2025, 7:00 AM EDT - 11 months ago

Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

Jul 31, 2025, 4:01 PM EDT - 11 months ago

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

MDT OBIO

Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 24, 2025, 7:00 AM EDT - 11 months ago

Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

Jul 10, 2025, 8:00 AM EDT - 1 year ago

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

Jul 2, 2025, 7:00 AM EDT - 1 year ago

Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics

Jul 2, 2025, 7:00 AM EDT - 1 year ago

Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics

Ligand Announces 2025 Investor Day in New York City

Jun 11, 2025, 7:00 AM EDT - 1 year ago

Ligand Announces 2025 Investor Day in New York City

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

Ligand Pharmaceuticals Earnings Call Transcript: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Ligand Pharmaceuticals Earnings Call Transcript: Q1 2025

Ligand Pharmaceuticals Quarterly report: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Ligand Pharmaceuticals Quarterly report: Q1 2025

Ligand Pharmaceuticals Earnings release: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Ligand Pharmaceuticals Earnings release: Q1 2025

Ligand Pharmaceuticals Slides: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Ligand Pharmaceuticals Slides: Q1 2025

Ligand Reports First Quarter 2025 Financial Results

May 8, 2025, 7:00 AM EDT - 1 year ago

Ligand Reports First Quarter 2025 Financial Results

Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 24, 2025, 7:00 AM EDT - 1 year ago

Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

Ligand Pharmaceuticals Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Ligand Pharmaceuticals Proxy statement: Proxy Filing

Ligand Pharmaceuticals Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Ligand Pharmaceuticals Proxy statement: Proxy Filing

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

Apr 17, 2025, 6:00 AM EDT - 1 year ago

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

Ligand Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 27, 2025, 8:30 AM EST - 1 year ago

Ligand Pharmaceuticals Earnings Call Transcript: Q4 2024

Ligand Pharmaceuticals Annual report: Q4 2024

Feb 27, 2025, 8:30 AM EST - 1 year ago

Ligand Pharmaceuticals Annual report: Q4 2024

Ligand Pharmaceuticals Earnings release: Q4 2024

Feb 27, 2025, 8:30 AM EST - 1 year ago

Ligand Pharmaceuticals Earnings release: Q4 2024

Ligand Pharmaceuticals Slides: Q4 2024

Feb 27, 2025, 8:30 AM EST - 1 year ago

Ligand Pharmaceuticals Slides: Q4 2024

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 7:00 AM EST - 1 year ago

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

Feb 25, 2025, 7:00 AM EST - 1 year ago

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

XOMA

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Feb 13, 2025, 7:00 AM EST - 1 year ago

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 6, 2025, 7:00 AM EST - 1 year ago

Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Ligand Pharmaceuticals Transcript: Investor Day 2024

Dec 10, 2024, 10:30 AM EST - 1 year ago

Ligand Pharmaceuticals Transcript: Investor Day 2024

Ligand Pharmaceuticals Slides: FY 2024

Dec 10, 2024, 10:30 AM EST - 1 year ago

Ligand Pharmaceuticals Slides: FY 2024

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

Dec 10, 2024, 9:00 AM EST - 1 year ago

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

Ligand to Present at Stifel 2024 Healthcare Conference

Nov 14, 2024, 8:00 AM EST - 1 year ago

Ligand to Present at Stifel 2024 Healthcare Conference

Ligand Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Ligand Pharmaceuticals Earnings Call Transcript: Q3 2024

Ligand Pharmaceuticals Quarterly report: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Ligand Pharmaceuticals Quarterly report: Q3 2024

Ligand Pharmaceuticals Earnings release: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Ligand Pharmaceuticals Earnings release: Q3 2024

Ligand Pharmaceuticals Slides: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Ligand Pharmaceuticals Slides: Q3 2024

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Nov 7, 2024, 7:00 AM EST - 1 year ago

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

Nov 1, 2024, 8:01 AM EDT - 1 year ago

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

Oct 23, 2024, 4:01 PM EDT - 1 year ago

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

Ligand Pharmaceuticals Slides: Corporate Presentation

Sep 10, 2024, 7:00 AM EDT - 1 year ago

Ligand Pharmaceuticals Slides: Corporate Presentation

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

Sep 6, 2024, 9:20 AM EDT - 1 year ago

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

TVTX

CD40 Ligand Market - Global Monoclonal Antibody, Polyclonal Antibody, Autoimmune Disease Treatment, Immunotherapy, Vaccine Development Forecast 2024-2030

Aug 30, 2024, 4:04 AM EDT - 1 year ago

CD40 Ligand Market - Global Monoclonal Antibody, Polyclonal Antibody, Autoimmune Disease Treatment, Immunotherapy, Vaccine Development Forecast 2024-2030

JamesTaulman
JamesTaulman Jun. 19 at 2:47 AM
$LGND – THU: Continued Bullish Action With Volume-Backed Gains to New Highs 8:30 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/thu-6-18-lgnd-continued-bullish-action-with-volume-backed-gains-to-new-highs/
0 · Reply
Jwa68
Jwa68 Jun. 18 at 12:42 PM
$PTHS A $1M insider purchase from the CEO of $LGND.. let that sit in...
0 · Reply
Doozio
Doozio Jun. 17 at 9:24 PM
$XBI has been up 12 of the last 13 months and 13 of the last 15 since 🐒🍌🧠⏰♾️ began. They did say it wud get $LGND ary with a $LEGN of huckleberries.
1 · Reply
Jwa68
Jwa68 Jun. 16 at 12:41 PM
$PTHS Not just anyone buying $1M worth, but the CEO of $LGND ....pretty telling.
0 · Reply
JamesTaulman
JamesTaulman Jun. 16 at 2:18 AM
$LGND – MON: Welcomed Quieter Trading After Several Sessions With Above Average Volume Gains 7:45 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/mon-6-15-lgnd-welcomed-quieter-trading-after-several-sessions-with-above-average-volume-gains/
0 · Reply
JamesTaulman
JamesTaulman Jun. 12 at 3:46 AM
$LGND – THU: Solid Gains With a +22% Increase in Volume – New High Close 11:00 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/thu-6-11-lgnd-solid-gains-with-a-22-increase-in-volume-new-high-close/
0 · Reply
JamesTaulman
JamesTaulman Jun. 11 at 2:45 AM
$LGND – WED: Jumped Higher Then Pulled Back – Next Support Is at the Round-$240 8:00 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/wed-6-10-lgnd-jumped-higher-then-pulled-back-next-support-is-at-the-round-240/
0 · Reply
xUltraCash
xUltraCash Jun. 10 at 2:22 PM
$LGND nice..
0 · Reply
JamesTaulman
JamesTaulman Jun. 10 at 2:53 AM
$LGND – TUE: Posts a New High Close Yet Volume Off -20% 8:45 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/tue-6-9-lgnd-posts-a-new-high-close-yet-volume-off-20/
0 · Reply
JamesTaulman
JamesTaulman Jun. 9 at 2:43 AM
$LGND – MON: Dealing With Some Noted Resistance of the Round-$240 9:30 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/mon-6-8-lgnd-dealing-with-some-noted-resistance-of-the-round-240/
0 · Reply
BioRich
BioRich Jun. 8 at 11:56 PM
$SGMT $LGND $HUMA $VVOS $GUTS Looks like this played out to be a great move. Haven't gotten back into $SGMT yet, but still on the radar. $GUTS was up massively and should retrace again. $HUMA has been excellent, $VVOS is gaining attention and traction. $LGND has been good, but I invested in them for long-term winner with their massive pipeline. Congrats to those that followed the play. For those that didn't, these all seem to have a lot of room to grow. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems (like these) and learn. Let's make some (more) money. Cheers!
1 · Reply
JamesTaulman
JamesTaulman Jun. 5 at 3:10 AM
$LGND – THU: Dropped From Its Highs Mid-Day – Watching the 10 DMA Support at $232.22 10:00 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/thu-6-4-lgnd-dropped-from-its-highs-mid-day-watching-the-10-dma-support-at-232-22/
0 · Reply
JamesTaulman
JamesTaulman Jun. 4 at 4:29 AM
$LGND – WED: Continued Trading Above the 10 DMA – Good Sign 8:00 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/wed-6-3-lgnd-continued-trading-above-the-10-dma-good-sign/
0 · Reply
JamesTaulman
JamesTaulman Jun. 3 at 3:32 AM
$LGND – TUE: Gains From the 10 DMA – Still Needs to Avoid Getting Into a Downtrend 8:00 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/tue-6-2-lgnd-gains-from-the-10-dma-still-needs-to-avoid-getting-into-a-downtrend/
0 · Reply
Quantumup
Quantumup Jun. 2 at 8:06 PM
H.C. Wainwright⬆️ $TVTX's PT to $67/reitd Buy after TVTX announced the licensing of civorebrutinib from Everest—they said—the early dev't/drug profile are pointing in the right direction/civerobrutinib has the pot'l to be a best-in-class BTK inhibitor $LGND SNY PFE $NVS Here's what else HCW said: https://x.com/Quantumup1/status/2061901622561935834?s=20
0 · Reply
you_got_jammed
you_got_jammed Jun. 2 at 6:56 PM
$LGND Solid but very under the radar biotech. I am surprised it hasn't been bought out yet. Huge pipeline.
0 · Reply
JamesTaulman
JamesTaulman Jun. 2 at 3:09 AM
$LGND – MON: Makes a Bounce From Support Offered by Its 10 DMA at $225.25 – Good Sign Latest Chart Update: LGND 9:25 PM – We are currently reporting on this stock as an active holding and continue to monitor the stock closely for any technical SELL SIGNALS. The focus always remains on price/volume action around key support levels, including the 10 DMA, 50 DMA, and any nearby trendline or ROUND-$ support. https://buyingbreakouts.com/mon-6-1-lgnd-makes-a-bounce-from-support-offered-by-its-10-dma-at-225-25-good-sign/
0 · Reply
JamesTaulman
JamesTaulman Jun. 2 at 2:20 AM
$LGND – MON: Makes a Bounce From Support of the 10 DMA – Good Sign 8:45 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/mon-6-1-lgnd-makes-a-bounce-from-support-of-the-10-dma-good-sign/
0 · Reply
JamesTaulman
JamesTaulman May. 29 at 2:01 AM
$LGND – THU: Welcomed Quieter Action as Resistance of the Previous Highs Come Into Play 8:00 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/thu-5-28-lgnd-welcomed-quieter-action-as-resistance-of-the-previous-highs-come-into-play/
0 · Reply
JamesTaulman
JamesTaulman May. 28 at 2:20 AM
$LGND – WED: A Bit Volatile After a Nice Run – Some Consolidation Here Would Be Ideal 8:00 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/wed-5-27-lgnd-a-bit-volatile-after-a-nice-run-some-consolidation-here-would-be-ideal/
0 · Reply
Estimize
Estimize May. 27 at 1:03 PM
Wall St is expecting 2.01 EPS for $LGND Q2 [Reporting 08/11 BMO] http://www.estimize.com/intro/lgnd?chart=historical&metric_name=eps&utm_co
0 · Reply
JamesTaulman
JamesTaulman May. 27 at 2:25 AM
$LGND – TUE: Shoots Higher +2.6% – Closed Near Session Highs – Volume Only Average 8:15 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/tue-5-26-lgnd-shoots-higher-2-6-closed-near-session-highs-volume-only-average/
0 · Reply